Synairgen plc (SYGGF)
OTC PINK OTC PINK Primary 
Synairgen shares stay tradeable post-delisting, as top investor waives restrictions
Synairgen PLC (AIM:SNG, OTC:SYGGF), a biotech company developing an experimental inhaled treatment for respiratory infections, says its shares will remain freely tradeable - even after its recent move to go private. The company, best known for its investigational drug SNG001, updated investors following a vote last week to delist from AIM and become a private limited company.
Synairgen becomes the latest company to eye the AIM exit door
Synairgen PLC (AIM:SNG, OTC:SYGGF) is set to become the latest in a growing wave of smaller companies leaving London's AIM market after struggling to lock down fresh investment. The biotech firm, which has been developing an inhaled treatment for respiratory infections, confirmed plans to cancel its AIM listing and go private after failing to meet fundraising targets.
Synairgen CEO on funding phase 2 trial for SNG001 - ICYMI
Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the company's recent fundraising efforts to support a phase II clinical trial. The study aims to test SNG001, a broad-spectrum inhaled antiviral, in critically ill patients requiring mechanical ventilation due to respiratory viruses.
Synairgen backer ready to pump £18-£19 million into phase II trial
Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £25 million to fund the development of SNG001, its investigational inhaled interferon beta treatment. The funding includes a subscription for between £18-£19 million and a £6 million placing and open offer.
Synairgen making substantial progress towards phase II trial
Synairgen PLC (AIM:SNG, OTC:SYGGF) said it has made 'substantial progress' preparing for a phase II trial of its lead asset, SNG001, which is being developed to treat high-risk patients with severe viral lung infections who are on ventilation. "Having closely analysed various routes forward, we are confident that our focus on these high-risk patients is optimal from both a clinical and commercial perspective," said CEO Richard Marsden.
Synairgen appoints inhaled drug development expert as chairman
Synairgen PLC (AIM:SNG, OTC:SYGGF) chairman Simon Shaw will retire at next month's annual shareholder meeting, to be replaced by Mark Parry-Billings, who he called "a world class inhaled drug development leader". Dr Parry-Billings was latterly global head of drug development at Italian respiratory and rare diseases giant Chiesi Farmaceutici, following a stint as CEO of Canadian clinical-stage respiratory biotech Topigen Pharmaceuticals until its acquisition by Pharmaxis in 2010.
Synairgen making plans for phase II trial
Synairgen PLC (AIM:SNG, OTC:SYGGF) said it is on the "verge of embarking" on a phase II trial of SNG001, for severe viral lung infection. The focus will be on patients who are mechanically ventilated.
